Bristol Myers Squibb Company
NEWS
Sage and Biogen announced positive topline results from the Phase III study of zuranolone that showed a rapid reduction in depressive symptoms after three days.
Bristol Myers Squibb and Exelixis reported two-year follow-up data from the Phase III trial of BMS’s checkpoint inhibitor Opdivo (nivolumab) and Exelixis’ Cabometyx (cabozantinib).
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended 14-1 that the two companies conduct a trial applicable to the U.S. population.
Gilead Sciences revealed in a call with analysts that the hold has now been expanded to additional magrolimab studies.
The FDA placed a partial clinical hold on studies conducted by Gilead Sciences assessing the combination of magrolimab plus azacitidine due to concerns of unexpected adverse events.
Metagenomi announced the completion of an oversubscribed $175 million Series B financing round, bringing the company’s total funding to $300 million.
Last week was a relatively quiet week for clinical trial news, particularly around COVID-19. Here’s a look.
The San Diego-based immunology company is locating and developing molecules where the mechanism of action has either been proven or makes sense.
January has been a largely quiet month for PDUFA dates on the U.S. Food and Drug Administration (FDA)’s calendar. There were two dates for the entire month, and one of those has been moved back to April. Here’s a look.
JOBS
IN THE PRESS